Patent intelligence · US
US 12414943
Nimodipine parenteral administration
Nimodipine parenteral administration
Patent details — US 12414943
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 16, 2025
- Expiration
- Sep 11, 2045
- Applicant
- Grace Therapeutics U.S., Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/4422, A61K47/10, A61K47/24
Quick answer
US 12414943 (Nimodipine parenteral administration) is held by Grace Therapeutics U.S., Inc.. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Grace Therapeutics U.S., Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/4422, A61K47/10, A61K47/24, A61K47/26, A61K47/40
More from Grace Therapeutics U.S., Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12049487
Universal chimeric antigen receptor T-cell preparation technique
granted -
US 11840575
Engineered immune cells targeting BCMA and their uses thereof
granted -
US 11484501
Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica
granted -
US 11478424
Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica
granted -
US 11478420
Vaginal probiotic products and related processes
granted -
US 11291672
Betamethasone oral spray formulation and method of use to treat ataxia
granted -
US 11052029
Cation compatible metal oxides and oral care compositions containing the metal oxides
granted
Frequently asked questions
What is US patent 12414943?
US 12414943 (Nimodipine parenteral administration) is held by Grace Therapeutics U.S., Inc.. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12414943?
Grace Therapeutics U.S., Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 12414943 expire?
Our index shows an expiration date of Sep 11, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.